Drug
Rentosertib
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Detail
Rentosertib is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF).
Study Purpose
The goal of this clinical trial is to learn about rentosertib in adults with IPF. The primary objective is to evaluate the safety and tolerability of rentosertib orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.